Form 4: SAB Biotherapeutics Director Helen K. Ellias Receives Stock Option Grants

Director Helen K. Ellias receives stock option grants as part of her board membership compensation.

Summary

• Helen K. Ellias, a director of SAB Biotherapeutics, Inc. (SABS), received two stock option grants on November 1, 2024.
• The first grant is an annual grant of 20,000 shares at an exercise price of $3.88, vesting in two equal annual installments starting November 1, 2025, and expiring on November 1, 2034.
• The second grant is an inaugural grant of 35,000 shares at an exercise price of $3.88, vesting in three equal annual installments starting November 1, 2025, and expiring on November 1, 2034.
• The grants were made under the company's 2021 Omnibus Equity Incentive Plan, as amended.
• Following the transaction, Ms. Ellias directly owns 55,000 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation event, which is generally viewed neutrally to positively as it aligns director interests with shareholders. The sentiment is slightly positive due to the incentive structure created by the vesting schedule.

Positives

• The stock option grants align the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock options are a common form of compensation for directors of publicly traded companies, aligning their interests with shareholders and incentivizing them to increase company value.

Comparison to Industry Standards

• Director compensation packages vary widely across the biotechnology industry, depending on company size, stage of development, and board responsibilities.
• Stock options are a typical component, often vesting over several years to encourage long-term commitment.
• Comparing the size and vesting schedule of these grants to those of directors at similar-stage biotech companies (e.g., those with comparable market capitalization and revenue) would provide a benchmark for assessing their competitiveness.

Stakeholder Impact

• Shareholders: The grants align the director's interests with those of the shareholders, incentivizing value creation.
• Employees: The grants are unlikely to have a direct impact on employees.
• Director: The grants provide additional compensation and incentivize long-term commitment to the company.

Key Dates